This study tests two different treatments for a specific type of breast cancer that has spread or can't be removed by surgery. The cancer has a PIK3CA mutation, which means there's a change in a gene that can affect cell growth. Patients have previously used a CDK4/6 inhibitor, a type of drug that helps stop cancer cells from dividing.
In this study, patients will be given either RLY-2608 (also called zovegalisib) with fulvestrant, or capivasertib with fulvestrant. Fulvestrant is a drug that blocks estrogen, which can help stop cancer growth.
- The study is for adults, both women and men, who meet certain health criteria.
- Participants must have cancer that has returned or worsened after previous treatments.
- People with certain health issues, like specific heart or lung diseases, or uncontrolled diabetes, cannot join.
It's important to consider the time commitment and possible side effects before joining. Participants will be closely monitored to ensure their safety throughout the study.
How understandable was the trial content above?
Hard to understand
Easy to understand